DRDO’s anti-Covid drug 2-DG launched

The drug has been developed by DRDO’s Institute of Nuclear Medicine and Allied Sciences (INMAS) in collaboration with Dr Reddy’s Laboratories
anti-COVID drug 2-DG
anti-COVID drug 2-DG

New Delhi, May 17 : The first batch of DRDO-developed anti-Covid drug 2-DG (2-deoxy-D-glucose) was launched on Monday to treat patients suffering from the deadly disease. The medicine comes in powder form and can be taken with water.

The drug has been developed by DRDO’s Institute of Nuclear Medicine and Allied Sciences (INMAS) in collaboration with Dr Reddy’s Laboratories. DRDO Chairman Dr G Satheesh Reddy said that DRDO and Dr Reddy’s lab had gone through the complete trials and conducted trials across 30 hospitals and on a large number of patients. The first batch of 10,000 doses of 2DG medicine would be launched early next week, informed DRDO officials told ANI on Friday.

The drug comes in powder form in a sachet, which is taken orally by dissolving it in water. It accumulates in the virus-infected cells and prevents virus growth by stopping viral synthesis and energy production. Its selective accumulation in virally infected cells makes this drug unique.

In the ongoing second COVID-19 wave, a large number of patients are facing severe oxygen dependency and need hospitalisation. The drug is expected to save precious lives due to the mechanism of operation of the drug in infected cells. This also reduces the hospital stay of COVID-19 patients.

Total
6
Shares
Related Posts